Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (3762)

Company Market Cap Price
SHPH Shuttle Pharmaceuticals Holdings, Inc.
Company is a oncology-focused biotech developing radiation sensitizers and HDAC inhibitor therapeutics, with lead assets in Phase 2/preclinical stages.
$1.30M
$3.00
-1.64%
ENVB Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
$1.17M
$5.62
-8.32%
AURX Nuo Therapeutics, Inc.
Aurix System is a wound care device used for chronic wounds (direct product).
$972618
$2.00
INIS International Isotopes Inc.
Core product: INIS manufactures radiopharmaceutical drugs (I-131) used for diagnostic imaging and therapy.
$967348
$0.10
MYNZ Mainz Biomed B.V.
PancAlert is a blood-based diagnostic test using biomarker panels (liquid biopsy) to detect pancreatic cancer, fitting the Liquid Biopsy investable theme.
$946703
$1.48
-1.67%
OGEN Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
$876899
$1.23
-0.41%
WLDS Wearable Devices Ltd.
Biometric authentication and biometric sensing features embedded in the Mudra platform align with Medical Devices & Biometrics.
$676231
$2.62
+1.95%
APVO Aptevo Therapeutics Inc.
APVO is a oncology-focused biotech developing novel immunotherapies, including mipletamig and other pipelines targeting cancer.
$628469
$1.54
+10.36%
SLRX Salarius Pharmaceuticals, Inc.
Salarius operates as a clinical-stage biotech focused on oncology therapies (e.g., LSD1 inhibitor seclidemstat) and develops cancer treatments.
$551676
$3.81
-0.91%
WOK WORK Medical Technology Group Ltd.
Company directly manufactures disposable medical device consumables sold globally (e.g., masks, breathing circuits, endotracheal tube holders).
$520550
$3.56
-5.32%
RGBP Regen BioPharma, Inc.
RGBP focuses on oncology/s Cancer immunotherapy and regenerative medicine, aligning with Biotech - Oncology.
$409265
$0.01
REVB Revelation Biosciences, Inc.
Core product focus on modulating innate immunity using the Gemini platform, aligning with Immunology Therapeutics.
$401581
$1.25
-0.40%
FCHS First Choice Healthcare Solutions, Inc.
The company is pivoting to operate outpatient primary care clinics / ambulatory services led by nurse practitioners.
$395499
$0.01
LADX LadRx Corporation
LadRx is a biotechnology company focused on oncology drug development.
$371319
$0.75
SGBX Safe & Green Holdings Corp.
Medical segment includes point-of-care solutions and the Sanitec disinfecting system, aligning with Medical Devices & Biometrics.
$366873
$2.30
+0.44%
ZVSA ZyVersa Therapeutics, Inc.
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, classifiable as Monoclonal Antibody Therapeutics.
$349274
$0.14
TIRX Tian Ruixiang Holdings Ltd
Core product is health insurance solutions enabled by AI-driven tech via Ucare platform.
$293128
$1.05
+7.14%
CDT CDT Equity Inc.
Pipeline targets inflammatory/autoimmune diseases, aligning with immunology therapeutics.
$283088
$2.81
-4.58%
MSPR MSP Recovery, Inc.
Biometric technology used for patient verification and data integrity.
$259087
$0.22
-29.66%
HSDT Solana Company
PoNS is a non-invasive neuromodulation device produced by the company for gait and balance rehabilitation.
$62732
$5.99
+0.17%
CERO CERo Therapeutics Holdings, Inc.
CER-T is a cell therapy platform with lead candidate CER-1236, indicating direct cell-based therapeutic products.
$27220
$0.10
+1.58%
PLRZ Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
$16496
$1.02
-0.97%
EMMA Emmaus Life Sciences, Inc.
Endari is an oral small-molecule therapeutic (L-glutamine) marketed by Emmaus Life Sciences for sickle cell disease.
$13057
$0.01
SMFL Smart for Life, Inc.
SMFL owns manufacturing facilities (BSNM and DSO) and provides contract manufacturing for branded and contract-made nutraceutical products.
$1366
$0.01
NCNA NuCana plc
NuCana is a clinical-stage oncology biotech focusing on cancer therapeutics (NUC-3373 and NUC-7738).
N/A
$4.04
+8.76%
← Previous
1 ... 36 37 38
Next →
Showing page 38 of 38 (3762 total stocks)

Loading company comparison...

Loading research report...

CERO CERo Therapeutics Holdings, Inc.

CERo Therapeutics Faces Nasdaq Listing Suspension After Panel Denial

Oct 29, 2025
HSDT Solana Company

Solana Company Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services

Oct 23, 2025
CERO CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Third Dose in AML Trial and Secures $2.3M Financing Tranche

Oct 21, 2025
WOK WORK Medical Technology Group Ltd.

WORK Medical Announces $1 Million Equity Investment in Neologics Bioscience

Oct 21, 2025
HSDT Solana Company

Solana Company (HSDT) Announces Effective Resale Registration of Shares Purchased in Recent Private Placement

Oct 20, 2025
WOK WORK Medical Technology Group Ltd.

WORK Medical Technology Group Receives Nasdaq Delisting Determination Letter

Oct 15, 2025
CERO CERo Therapeutics Holdings, Inc.

CERo Therapeutics Completes First Cohort of Phase 1 CER‑1236 AML Trial

Oct 13, 2025
PLRZ Polyrizon Ltd.

Polyrizon Announces Positive Pre‑Clinical Results for PL‑14 Allergy Blocker

Oct 06, 2025
PLRZ Polyrizon Ltd.

Polyrizon Submits Pre-Submission Package to FDA for PL-14 Allergy Blocker

Sep 19, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Secures $9.6 Million from Warrant Exercise

Sep 11, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Sep 09, 2025
PLRZ Polyrizon Ltd.

Polyrizon Regains Full Compliance with Nasdaq Listing Requirements

Aug 14, 2025
OGEN Oragenics, Inc.

Oragenics Provides Q2 2025 Shareholder Update, Reports Reduced Net Loss and Increased Cash Position

Aug 11, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Reports Q2 2025 Financial Results, Anticipates Phase 1b Data

Aug 08, 2025
REVB Revelation Biosciences, Inc.

Former Revelation Biosciences Chairman George Tidmarsh Appointed Head of FDA CDER

Jul 24, 2025
PLRZ Polyrizon Ltd.

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Preclinical Study

Jul 22, 2025
OGEN Oragenics, Inc.

Oragenics Secures U.S.-Based Drug Manufacturing Agreement with Sterling Pharma Solutions for ONP-002

Jul 16, 2025
PLRZ Polyrizon Ltd.

Polyrizon Retains Nasdaq Listing Following Hearings Panel Decision, Warrants Fully Exercised

Jul 15, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Completes Dosing in PRIME Phase 1b Clinical Study

Jul 15, 2025
OGEN Oragenics, Inc.

Oragenics Completes $16.5 Million Public Offering of Preferred Stock and Warrants

Jul 02, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Jul 02, 2025
PLRZ Polyrizon Ltd.

Polyrizon Reports Promising Preclinical Results for Trap & Target Platform in CNS Drug Delivery

Jun 12, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Closes $4 Million Public Offering to Fund Development

May 29, 2025
OGEN Oragenics, Inc.

Oragenics Announces One-for-Thirty Reverse Stock Split

May 28, 2025
PLRZ Polyrizon Ltd.

Polyrizon Receives Nasdaq Delisting Notice Citing Substantial Dilution from Private Placement Warrants

May 23, 2025
REVB Revelation Biosciences, Inc.

George Tidmarsh Retires from Revelation Biosciences Board Due to Potential Conflict

May 23, 2025
OGEN Oragenics, Inc.

Oragenics Receives Approval to Initiate Phase II Concussion Drug Trial in Australia

May 13, 2025
OGEN Oragenics, Inc.

Oragenics Reports Q1 2025 Net Loss of $2.22 Million

May 09, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Reports Q1 2025 Financials, Faces Going Concern Challenge

May 08, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Expands Gemini Pipeline to Include Severe Burn Infection Prevention

Apr 29, 2025
PLRZ Polyrizon Ltd.

Polyrizon Reports Successful Preliminary Safety Study for PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 25, 2025
PLRZ Polyrizon Ltd.

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Price Non-Compliance

Apr 11, 2025
OGEN Oragenics, Inc.

Oragenics Submits Clinical Trial Protocol to New Zealand Ethics Committee for ONP-002 Phase IIa Trial

Apr 09, 2025
PLRZ Polyrizon Ltd.

Polyrizon Engages Branding Firm for Strategic Brand Development of C&C Hydrogel Technology

Apr 02, 2025
PLRZ Polyrizon Ltd.

Polyrizon Ltd. Closes $17.0 Million Private Placement, Bolstering Capital Resources

Apr 01, 2025
PLRZ Polyrizon Ltd.

Polyrizon Ltd. Announces $17.0 Million Private Placement with Institutional Investors

Mar 31, 2025
OGEN Oragenics, Inc.

Oragenics Provides Q1 2025 Shareholder Update, Highlights $5 Million in New Funding

Mar 27, 2025
PLRZ Polyrizon Ltd.

Polyrizon Structures Clinical Strategy for PL-14 Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 27, 2025
PLRZ Polyrizon Ltd.

Polyrizon Initiates Preclinical Studies for Intranasal Benzodiazepines Targeting Epilepsy Rescue Treatment

Mar 25, 2025
REVB Revelation Biosciences, Inc.

Gemini Priming Attenuates Inflammation in Human PBMCs, Supporting Clinical Potential

Mar 17, 2025
OGEN Oragenics, Inc.

Oragenics Files 2024 Annual Report on Form 10-K with Going Concern Warning

Mar 14, 2025
PLRZ Polyrizon Ltd.

Polyrizon Signs LOI to Develop Intranasal Psychedelic-Based Treatments

Mar 14, 2025
PLRZ Polyrizon Ltd.

Polyrizon Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2024

Mar 11, 2025
PLRZ Polyrizon Ltd.

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose

Mar 10, 2025
OGEN Oragenics, Inc.

Oragenics Submits Investigator's Brochure for ONP-002 Phase II Clinical Trial in Australia

Mar 06, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Reports Full Year 2024 Financial Results, Focuses on Clinical Advancement

Mar 06, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Doses First Patient in PRIME Phase 1b CKD Study

Feb 26, 2025
REVB Revelation Biosciences, Inc.

Revelation Biosciences Secures Full NASDAQ Listing Approval

Feb 24, 2025
OGEN Oragenics, Inc.

Oragenics Announces Strategic Partnership with BRAINBox Solutions to Revolutionize Concussion Care

Feb 11, 2025
PLRZ Polyrizon Ltd.

Polyrizon Files Divisional Patent Application for Trap & Target™ Intranasal Drug Delivery Platform in Israel

Jan 30, 2025

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks